In non‐small cell lung cancer, SSRIs limit tumor growth and increase tumor sensitivity to erlotinib by inhibiting the adenosine 5‐monophosphate adenosine 5‘‐monophosphate (AMP)‐activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling pathway [220]. The gene discussed is MTOR; the disease is neoplasm.